Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future
Up to $55 million in committed financing requires court approval, while the sale process will allow competing bids.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Karyopharm Therapeutics (Nasdaq: KPTI) has agreed to a planned merger with Ayrmid through a court-supervised restructuring and sale process. Karyopharm entered a Restructuring Support Agreement with existing lenders, noteholders and other stakeholders, and filed voluntary Chapter 11 petitions in the U.S. Bankruptcy Court for the Southern District of Texas.
Ayrmid will serve as lead bidder. Karyopharm will seek court approval of bidding procedures allowing competing proposals for its assets. The transaction is expected to close in the first quarter of 2027, subject to conditions in the Chapter 11 plan. Existing secured lenders committed up to $55 million in debtor-in-possession financing, subject to court approval. Karyopharm expects that funding and operating cash generation to support its business and post-filing obligations, with operations continuing uninterrupted as it advances its multiple myeloma and myelofibrosis programs.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.Up to $55 million in financing commitments from existing secured lenders would support the Chapter 11 process. 3.7× market cap
- Moderate point. Forward-looking: it has not happened yet and may not happen.Ayrmid merger agreement establishes a proposed transaction with a reorganized Karyopharm.
- Minor point. Forward-looking: it has not happened yet and may not happen.Operations are expected to continue uninterrupted while Karyopharm advances its multiple myeloma and myelofibrosis programs.
Negative
- Major pointVoluntary Chapter 11 filings place Karyopharm in a court-supervised restructuring process.
- Major point. Forward-looking: it has not happened yet and may not happen.Debtor-in-possession financing adds borrowing and requires court approval before becoming available.
- Moderate pointCompeting-bid procedures require court approval, with Ayrmid serving as lead bidder rather than a completed merger partner.
- Minor point. Forward-looking: it has not happened yet and may not happen.Expected first-quarter 2027 closing remains subject to conditions in the Chapter 11 plan.
News Explained
The release describes a planned merger of Ayrmid with reorganized Karyopharm through a Chapter 11 plan but does not specify merger consideration or ownership allocation for existing common holders.
Details
Market move: KPTI -59.21% vs previous close. Chapter 11 merger agreement
On Nov 2, the day this news came out, the latest delayed price for KPTI is 59.21% below the previous close. Argus tracked a trough of -58.4% from its starting point during tracking. Our momentum scanner has recorded 38 alerts for this stock so far that day. The latest delayed price is $0.27. Relative volume is exceptionally heavy at 480.2x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- DIP financing commitment
- Up to $55 million
- From existing secured lenders; subject to Court approval
- Expected transaction close
- First quarter of 2027
- Subject to conditions described in the Chapter 11 plan
Historical Context
-
Reported a September loan payment and minimum liquidity covenant while evaluating financing alternatives.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restructuring support agreement financial
chapter 11 regulatory
debtor-in-possession financing financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
– The Company Remains Focused on Supporting Patients and Advancing its Programs in Multiple Myeloma and Myelofibrosis –
– Ayrmid will Serve as Lead Bidder in Court-Supervised Sale Process to Maximize Business Value for all Stakeholders –
– The Company Receives a Commitment of
To implement the Transaction, Karyopharm has filed voluntary petitions under Chapter 11 of the
"Following a comprehensive review of available alternatives, we believe this process provides a clear framework to pursue a value maximizing transaction for our stakeholders while continuing our important work of advancing therapies for patients with multiple myeloma and myelofibrosis," said Richard Paulson, President and Chief Executive Officer at Karyopharm. "We are pleased to have signed an agreement with Ayrmid, a company committed to advancing meaningful therapies for patients with hematological disorders. Ayrmid's proposal underscores the strategic interest in our programs and establishes a strong foundation as we move through this process designed to maximize value. Throughout, we will remain focused on supporting our employees, maintaining continuity across the business, and advancing our mission to improve the lives of patients."
"We see a strong strategic fit between Ayrmid and Karyopharm, with complementary portfolios, established commercial capabilities and a shared commitment to addressing significant unmet needs in hematology," said Dr. Joe Wiley, Chairman and CEO of Ayrmid. "We see considerable potential in Karyopharm's marketed products, development pipeline and experienced team, and believe that, together, we can build a broader, stronger commercial-stage hematology business with meaningful opportunities for future growth. Subject to the successful completion of the transaction, we look forward to working with the Karyopharm team to realize that potential and continue delivering important therapies to patients in need."
In connection with this process, Karyopharm has secured commitments for up to
Karyopharm is prepared to move through this process quickly and efficiently without any disruption to either its ordinary course operations or the partnerships essential to supporting Karyopharm's patients and advancing its programs.
Parties interested in participating in Karyopharm's sale process should contact Centerview Partners at centerview@karyopharm.com.
Additional Information
Additional information about Karyopharm's restructuring process is available at https://cases.stretto.com/KPTI, or by contacting Stretto, the Company's noticing and claims agent, at (866) 270-4922 (toll-free) and (949) 561-0471 (international).
Karyopharm is advised in this matter by Sidley Austin LLP as legal counsel, Centerview Partners LLC as investment banker and FTI Consulting Inc. as financial and communications advisor.
An ad hoc group of term lenders and noteholders is advised in this matter by Latham & Watkins LLP and Haynes and Boone LLP as legal counsel and Houlihan Lokey Capital, Inc. as investment banker and financial advisor.
Ayrmid is advised in this matter by Paul Hastings LLP as legal counsel.
About Karyopharm Therapeutics
Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. The Company's lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the
About Ayrmid
Ayrmid, Ltd., the parent company of Gamida Cell Inc., is a commercial-stage biotechnology company focused on delivering differentiated therapies that address significant unmet needs in haematology. With established commercial infrastructure in the United States and an international distribution network serving markets outside the US, Ayrmid has built a platform to support the commercialisation of specialised therapies globally. Ayrmid currently has two FDA-approved products, Omisirge® (omidubicel-onlv) and APHEXDA® (motixafortide). Omisirge® (omidubicel-onlv) is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy approved to treat adults and pediatric patients 12 years and older with hematologic malignancies, and adults and pediatric patients 6 years and older with severe aplastic anemia (SAA) (please see the current full Prescribing Information here). APHEXDA® (motixafortide) is a CXCR4 antagonist approved to mobilize hematopoietic stem cells in adult patients with multiple myeloma (please see the current full Prescribing Information here). For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn, X, Facebook or Instagram.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the voluntary petitions under Chapter 11 (the "Cases"), Karyopharm's expectations with respect to its ability to consummate the transactions contemplated by the Restructuring Support Agreement, obtain Court approval of, and access to, the DIP Facility, and continue operating in the ordinary course while the Cases are pending, the timing of the Transaction closing, the ability of the Company to meet its financial obligations, and other statements that are not historical fact. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in these forward-looking statements. These risks and uncertainties include, but are not limited to: (i) risks related to the consummation of the transactions contemplated by the Restructuring Support Agreement; (ii) potential adverse effects of the Cases on the Company's liquidity and results of operations; (iii) the Company's ability to obtain timely approval by the Court of the motions filed in the Cases, including with respect to the DIP Facility and the bidding procedures; (iv) objections to the transactions contemplated by the Restructuring Support Agreement and/or the Chapter 11 Plan of Reorganization (the "Plan"), the bidding procedures or other pleadings filed that could protract the Cases; (v) employee attrition and the Company's ability to retain senior management and other key personnel due to the distractions and uncertainties; (vi) the Company's ability to comply with the restrictions imposed by the terms and conditions of the Company's financing arrangements, including the DIP Facility; (vii) the Company's ability to maintain relationships with suppliers, vendors, collaboration and license partners, employees and other third parties and regulatory authorities as a result of the Cases; (viii) the effects of the Cases on the Company and on the interests of various constituents, including holders of the Company's common stock and the Convertible Preferred Stock; (ix) the Court's rulings in the Cases, including the approval of the terms and conditions of the transactions contemplated by the Restructuring Support Agreement or the Plan, and the outcome of the Cases generally; (x) the length of time that the Company will operate under Chapter 11 protection and the continued availability of operating capital during the pendency of the Cases; (xi) risks associated with third party motions in the Cases, which may interfere with the Company's ability to consummate the transactions contemplated by the Restructuring Support Agreement Plan or an alternative transaction; (xii) increased administrative and legal costs related to the Chapter 11 process; (xiii) exposure to potential litigation, including related to the transactions contemplated by the Restructuring Support Agreement or the Plan, and inherent risks involved in a bankruptcy process; (xiv) the occurrence of any event, change or other circumstances that could give rise to the right of any parties to the Restructuring Support Agreement to terminate the Restructuring Support Agreement; (xv) the possibility that the anticipated benefits of the transactions contemplated by the Restructuring Support Agreement or the Plan are not realized when expected or at all; (xvi) diversion of management's attention from ongoing business operations and opportunities; (xvii) potential adverse reactions or changes to business or employee relationships, including those resulting from the bankruptcy proceedings of the Company or the announcement or completion of the transactions contemplated by the Restructuring Support Agreement or the Plan; (xviii) the expected delisting of the Company's common stock from the Nasdaq Global Select Market; and (xix) other risks and uncertainties, including those described in the section entitled "Risk Factors" in the Company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and in other filings the Company makes with the SEC from time to time. The forward-looking statements herein do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by law, Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact
Brendan Strong
Senior Vice President, Investor Relations
617.762.2661
Brendan.Strong@karyopharm.com
Media Contact
Rachel Chesley / Misha Ross
KaryopharmComms@fticonsulting.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-inc-announces-planned-merger-with-ayrmid-ltd-to-strengthen-company-for-the-future-302926356.html
SOURCE Karyopharm Therapeutics Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is Karyopharm's planned merger with Ayrmid, and when is it expected to close?
The planned transaction would merge Ayrmid with a reorganized Karyopharm through a Chapter 11 plan, with closing expected in the first quarter of 2027. Completion remains subject to conditions in that plan. Ayrmid will serve as lead bidder in a sale process allowing competing proposals.
How much financing has Karyopharm secured for its Chapter 11 process?
Karyopharm has secured commitments for up to $55 million in debtor-in-possession financing from existing secured lenders, subject to court approval. The company expects this financing, together with cash generated by ongoing operations, to support the business during Chapter 11 and meet financial obligations arising after the filing date.